The result is a paradox. Even before the HTA Review is formally concluded, announced, and implemented, the environment it was meant to reform has already worsened. Expectations that the review would stabilise or improve conditions now need to be recalibrated. The baseline has moved, and not in a favourable direction. …
To what extent does the system even see itself as bound by external review?
March 25, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Australian dementia experts push back on Cochrane Review, defending new treatments
April 20, 2026 - - Latest News -
Australia’s drug pricing dogma risks failing patients in the face of international realities
April 20, 2026 - - Latest News -
Free RSV vaccines roll out to protect senior Australians ahead of winter
April 20, 2026 - - Latest News -
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News